Group 1 - Core viewpoint: Bailin Ke Medical Technology (Shanghai) Co., Ltd. has completed its IPO counseling record with the Shanghai Securities Regulatory Bureau and plans to list on the A-share market, with CITIC Securities as the counseling institution [1] - Company establishment: Bailin Ke was established on September 10, 2021, with a registered capital of 360 million yuan, and is a high-tech group enterprise providing process solutions for the life sciences sector [1] - Business focus: The company specializes in the research and manufacturing of key process equipment and consumables for the production of recombinant protein drugs, vaccines, antibody drugs, cell therapy, gene therapy, and other biological products [1] Group 2 - Sales and service points: Bailin Ke has sales service points in cities including Beijing, Shanghai, Guangzhou, Chengdu, Suzhou, Wuhan, Jinan, and Changchun, and has established a research and application demonstration center in Suzhou [2] - International expansion: The company has opened subsidiaries in Germany and Singapore to support its international business expansion strategy [2] - Shareholder structure: The controlling shareholder is Hainan Bailin Ke Technology Investment Center (Limited Partnership), holding a direct stake of 27.8%, with other investors including KKR, Yahui Investment, Qingsong Capital, Shenzhen Capital Group, and Haiwang Capital [2]